BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells - Test2 - elhamkhani - TriplyDB

BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells

BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells

http://www.wikidata.org/entity/Q34123904

about

Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.The role of podoplanin in the biology of differentiated thyroid cancers.Association between BRAFV600E mutation and the clinicopathological features of solitary papillary thyroid microcarcinoma.Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways Molecular pathogenesis and mechanisms of thyroid cancer IQGAP1 plays an important role in the invasiveness of thyroid cancer MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals Recent advances in molecular diagnosis of thyroid cancer.Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer BRAF mutation in papillary thyroid carcinoma Selective Raf inhibition in cancer therapy.Recent advances in molecular biology of thyroid cancer and their clinical implications.The Na+/I- symporter (NIS): mechanism and medical impact.Expression Profiling of a Human Thyroid Cell Line Stably Expressing the BRAFV600E Mutation.BRAF mutation testing in clinical practice.Papillary microcarcinoma of the thyroid: clinical characteristics and BRAF(V600E) mutational status of 977 cases.Genetics and epigenetics of sporadic thyroid cancer.Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation.Cytotoxic and genotoxic effects of 131 I and 60 Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment.Is BRAF mutation screening useful for preoperative risk stratification in papillary thyroid cancer?BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer.BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma.Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT.BRAFV600E mutation and papillary thyroid cancer: chicken or egg?BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.Advanced Thyroid Cancer Patients in Phase I Clinical Trials: Outcome Assessment and Literature Review.BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas.The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells A somatic mutation of RasGRP3 decreases Na/I symporter expression in metastases of radioactive iodine-refractory thyroid cancer by stimulating the Akt signaling pathway

P2860

Q24309898-68A490F3-203C-4B72-988B-0786DC0CA1D8 Q33480990-908D47F6-B121-452D-959C-2B6398916458 Q33514138-90E47912-E447-4149-894C-F7700A0EE9AC Q33568168-282BEE37-13B4-481A-9015-994B933E4ADB Q33597740-BA74177D-2E80-4AE9-BF90-E602ACF80B62 Q33801421-2D22636C-E892-4CDC-B0CE-77D9A90A553F Q34329018-1C713686-9E47-478C-8B4D-743658D54DEE Q34420079-26C6BFA6-8127-4CFC-910F-16EA723B7FFC Q34721752-8EAA4CF8-4B33-46DA-B718-987659840325 Q34985320-F618F092-984B-4E59-848E-26E372DBF427 Q35421479-B5FDF3F6-2520-4030-9C2A-D41381940D9C Q35543644-F93ABEBA-36A6-4122-828D-926ADFF0FA82 Q35908104-F26D16C3-3EB2-4C34-B3E8-09A250FC5EB0 Q36238518-9EBA7926-1C83-4120-8263-C9560F2FB230 Q37004743-7E6429F1-08C2-456C-982E-79F4CA3753E9 Q37041330-88F0E9A3-92AB-4E6C-8A85-56B5C01A00FF Q37494004-00D8D746-CF48-4198-B8E0-9F0DE78B4A41 Q37607913-7FC96602-DCDF-4891-9540-356E89D79B63 Q37988572-B21D7BC2-A7F0-47E2-9F7A-9788533060C6 Q38078223-28E741F1-9348-40D9-9F1A-DC55B210C9E3 Q38128097-87BC08FA-0F63-44E2-A180-2E388F7CB228 Q38339382-1B93DDB2-9868-426A-B23E-7C35DCE51B53 Q38701744-71CA6392-2E0B-4672-94F8-4177B6F3C6F8 Q39936134-A92DD778-EA34-4604-B8BC-E2A779AC4752 Q40031893-AFDF176B-8810-41F3-B555-F642926A5A95 Q41607670-4AACDA0C-6801-403A-890A-92A6D019A19C Q41821409-DA990B4A-43B8-4D86-B8E7-3E05A0629882 Q42016940-8B923E2B-1F70-484A-851F-56770B5A1227 Q42707282-EC16A157-615E-4E2D-9463-218FECF68180 Q47106475-73EB2CE4-4F8F-426B-8AF5-8CD741EB497D Q47123617-6E88C138-C095-4F85-9E9D-EE44DB534364 Q54518460-172ABFF2-C46F-4E94-9B5D-C18EAB2FAF49 Q57150715-3655E1A8-5A18-41C4-8486-CDAA637D2A55 Q57494116-2C7888E5-A938-435F-8768-9551AD77A184

P2860

BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells

http://www.wikidata.org/entity/Q34123904

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@ast

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@en

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@nl

type

label

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@ast

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@en

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@nl

prefLabel

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@ast

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@en

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@nl

P1433

Q34123904-C71DDF40-2528-407C-A774-1046D0D7CDCC

P1476

Q34123904-99D2AA03-F3E8-4CCC-AD54-8E1F485E25BC

P2093

Q34123904-569444A1-4165-4419-8678-234FC70DA5D4

Q34123904-788DFED8-FA40-4143-A679-AC58CA7B63F6

Q34123904-AD317AF9-1973-48EB-8C15-1E36A768FD1E

Q34123904-BA2FCCF1-480C-4790-8C75-ADA66BF5B2AE

P2860

Q34123904-0681B1C7-8E14-4C06-B09E-5018BD4442BB

Q34123904-08D7589E-20F4-4DFA-B2CF-9B0C1204A95C

Q34123904-0BE2C0D2-B786-497E-B18C-37F300FFDA44

Q34123904-0F744709-4A7F-4639-B6BB-FB71CFDFDBA6

Q34123904-32A26DEC-5451-4629-9F9F-73C7D1EEB26D

Q34123904-362B2E1A-3A1C-4711-8EC9-1FF8107D311B

Q34123904-5855C008-B448-4EF3-B38E-775EEA7EFA01

Q34123904-5A831737-25B9-4067-A411-C2238A755B00

Q34123904-68FB815B-EE69-4281-9C5B-6BF6B32548D3

Q34123904-841B745D-58E2-418F-9056-FF8299CA40D6

P304

Q34123904-21C9E1D0-6DD8-4F7F-BD8B-622275BB4BC4

P31

Q34123904-58A5AB28-D0D5-4BBB-A5C0-BCE965B24C5F

P356

Q34123904-D6B815DC-E7F2-433F-88F9-33858B681921

P407

Q34123904-D019FD38-E4F5-48B9-9078-2FAA3E35965E

P433

Q34123904-E95081C8-6716-4A92-AD17-C4AFD0610276

P478

Q34123904-A8705E0D-41AB-4561-B5A7-4DAC7B0F4321

P577

Q34123904-DBD9ADCC-9270-43AD-91C9-9C3CEE7A2085

P5875

Q34123904-59F3C27B-9D02-4E73-A96F-FC3738A714F2

P698

Q34123904-37182406-1645-477D-A1F1-0F5B5E60B23D

P932

Q34123904-32E4163F-756E-42FA-B3A0-FDC3D109CB08

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

BRAF V600E maintains prolifera ...... papillary thyroid cancer cells

@en

P2093

Dingxie Liu

http://www.w3.org/2001/XMLSchema#string

Mingzhao Xing

http://www.w3.org/2001/XMLSchema#string

Stephen Condouris

http://www.w3.org/2001/XMLSchema#string

Zhi Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of the BRAF gene in human cancer

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

Guilty as charged: B-RAF is a human oncogene

Astrocyte-derived transforming growth factor-{beta} mediates the neuroprotective effects of 17{beta}-estradiol: involvement of nonclassical genomic signaling pathways

A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas.

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.

Raf proteins and cancer: B-Raf is identified as a mutational target.

BRAF mutation in thyroid cancer.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

P304

2264-2271

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2006-1613

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6432110

http://www.w3.org/2001/XMLSchema#string

P698

17374713

http://www.w3.org/2001/XMLSchema#string

P932

4152621

http://www.w3.org/2001/XMLSchema#string